US Patent Issued to ARCUTIS Biotherapeutics on March 25 for "Inhibition of crystal growth of roflumilast" (Colorado Inventor)

ALEXANDRIA, Va., March 26 -- United States Patent no. 12,257,242, issued on March 25, was assigned to ARCUTIS Biotherapeutics Inc. (Westlake Village, Calif.).

"Inhibition of crystal growth of roflumilast" was invented by David W. Osborne (Fort Collins, Colo.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodieste...